Rona Therapeutics Collaborated with Sanofi for siRNA Therapeutic Portfolio and Technology Platform
Shots:
- Sanofi to receive an up front & additional development & commercial milestones along with royalties
- Rona to acquire exclusive rights globally to expand Sanofi siRNA portfolio in liver & other non-liver applications & also has the rights to develop, manufacture & commercialize the products from 4 liver-targeting preclinical programs. Sanofi gets an exclusive option for neuro & muscular disease candidates discovered using the siRNA platform for territories outside of mainland China, Hong Kong, Taiwan & Macao
- The siRNA platform was developed based on novel nucleotide analogs & conjugation moieties which resulted in increased stability & in vivo duration of action, a possibility for therapeutic silencing of target genes in multiple tissue types
Ref: PRNewswire | Image: Sanofi
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
